{"title":"临终关怀的新闻","authors":"","doi":"10.1177/104990910402100603","DOIUrl":null,"url":null,"abstract":"Research published in the September 2004 issue of the Journal of Pain and Symptom Management reports that patients enrolled in hospice care cost Medicare less. The study, “Medicare Cost in Matched Hospice and NonHospice Cohorts,” also revealed that hospice patients lived longer, on average, than similar patients who did not choose hospice care. Commissioned by the National Hospice and Palliative Care Organization (NHPCO) and conducted by the actuarial firm of Milliman, USA, the study’s goal was to identify cost differences between patients who elect and do not elect to receive Medicare-paid hospice benefits. According to the research, the majority of patients with 16 of the most common terminal diagnoses who choose hospice care cost Medicare less. Cost savings range from $1,115 for rectal cancer patients to $8,879 for congestive heart failure patients. Researchers also found that, on average, hospice patients lived longer. These life spans range from 20 days for patients with a diagnosis of gallbladder cancer to 69 days for those with breast cancer. “With almost 30 percent of Medicare costs going for all types of care delivered towards the end of life, an understanding of the cost benefits of hospice is important,” said J. Donald Schumacher, president and CEO of NHPCO. “However, discussions relating to costs should never cloud the most important issue— hospice provides the highest quality of compassionate care for patients and families.” A significant factor in this study is the unique methodology used to work towards eliminating selection bias. Selection bias has been a recognized problem in previous studies contrasting hospice versus nonhospice patients. Medicare health insurance claims and enrollment data were used to measure both costs and time until death, starting from narrowly defined dates. Indicative markers were identified that represented unambiguous points in the end stage of each disease. This study began tracking patients further upstream in a manner that researchers suggest addresses many selection bias concerns. The data source was Medicare health insurance claims and enrollment data from 5 percent Sample Beneficiary Standard Analytic Files for years 1998, 1999, and 2000. This 5 percent sample is created by the Centers for Medicare & Medicaid Services as a statistically representative, longitudinal data set. The research includes 8,700 patients who met the criteria for this study. The article points out that a period of at least two to three months of hospice care may be optimal from both a cost and clinical standpoint. (Source: NHPCO press release, September 21, 2004.)","PeriodicalId":7716,"journal":{"name":"American Journal of Hospice and Palliative Medicine®","volume":"163 1","pages":"411 - 413"},"PeriodicalIF":0.0000,"publicationDate":"2004-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Hospice news\",\"authors\":\"\",\"doi\":\"10.1177/104990910402100603\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Research published in the September 2004 issue of the Journal of Pain and Symptom Management reports that patients enrolled in hospice care cost Medicare less. The study, “Medicare Cost in Matched Hospice and NonHospice Cohorts,” also revealed that hospice patients lived longer, on average, than similar patients who did not choose hospice care. Commissioned by the National Hospice and Palliative Care Organization (NHPCO) and conducted by the actuarial firm of Milliman, USA, the study’s goal was to identify cost differences between patients who elect and do not elect to receive Medicare-paid hospice benefits. According to the research, the majority of patients with 16 of the most common terminal diagnoses who choose hospice care cost Medicare less. Cost savings range from $1,115 for rectal cancer patients to $8,879 for congestive heart failure patients. Researchers also found that, on average, hospice patients lived longer. These life spans range from 20 days for patients with a diagnosis of gallbladder cancer to 69 days for those with breast cancer. “With almost 30 percent of Medicare costs going for all types of care delivered towards the end of life, an understanding of the cost benefits of hospice is important,” said J. Donald Schumacher, president and CEO of NHPCO. “However, discussions relating to costs should never cloud the most important issue— hospice provides the highest quality of compassionate care for patients and families.” A significant factor in this study is the unique methodology used to work towards eliminating selection bias. Selection bias has been a recognized problem in previous studies contrasting hospice versus nonhospice patients. Medicare health insurance claims and enrollment data were used to measure both costs and time until death, starting from narrowly defined dates. Indicative markers were identified that represented unambiguous points in the end stage of each disease. This study began tracking patients further upstream in a manner that researchers suggest addresses many selection bias concerns. The data source was Medicare health insurance claims and enrollment data from 5 percent Sample Beneficiary Standard Analytic Files for years 1998, 1999, and 2000. This 5 percent sample is created by the Centers for Medicare & Medicaid Services as a statistically representative, longitudinal data set. The research includes 8,700 patients who met the criteria for this study. The article points out that a period of at least two to three months of hospice care may be optimal from both a cost and clinical standpoint. (Source: NHPCO press release, September 21, 2004.)\",\"PeriodicalId\":7716,\"journal\":{\"name\":\"American Journal of Hospice and Palliative Medicine®\",\"volume\":\"163 1\",\"pages\":\"411 - 413\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2004-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American Journal of Hospice and Palliative Medicine®\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/104990910402100603\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Hospice and Palliative Medicine®","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/104990910402100603","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

2004年9月发表在《疼痛与症状管理杂志》上的一项研究报告称,参加临终关怀的病人花费较少的医疗保险费用。这项名为“匹配临终关怀和非临终关怀队列的医疗保险成本”的研究还显示,临终关怀患者的平均寿命比没有选择临终关怀的类似患者更长。受美国国家临终关怀和姑息治疗组织(National Hospice and Palliative Care Organization,简称NHPCO)委托,美国Milliman精算公司进行的这项研究的目标是确定选择和不选择接受医疗保险支付的临终关怀福利的患者之间的成本差异。根据这项研究,大多数患有16种最常见的晚期诊断的患者选择临终关怀的费用更低。节省的费用从直肠癌患者1115美元到充血性心力衰竭患者8879美元不等。研究人员还发现,平均而言,临终关怀病人的寿命更长。这些寿命从诊断为胆囊癌的20天到诊断为乳腺癌的69天不等。NHPCO总裁兼首席执行官j·唐纳德·舒马赫(J. Donald Schumacher)表示:“由于近30%的医疗保险费用用于临终关怀,了解临终关怀的成本效益非常重要。”“然而,有关费用的讨论不应该掩盖最重要的问题——临终关怀为病人和家属提供了最高质量的慈悲关怀。”本研究的一个重要因素是用于消除选择偏差的独特方法。在以往的安宁疗护病人与非安宁疗护病人的对比研究中,选择偏倚是一个公认的问题。医疗保险索赔和登记数据被用来衡量成本和死亡前的时间,从狭义的定义日期开始。确定了指示性标记,代表了每种疾病终末期的明确点。这项研究以一种研究人员提出的解决许多选择偏差问题的方式开始进一步追踪患者。数据来源是1998年、1999年和2000年5%样本受益人标准分析文件中的医疗保险健康保险索赔和登记数据。这5%的样本是由医疗保险和医疗补助服务中心创建的,作为统计代表性的纵向数据集。该研究包括8700名符合本研究标准的患者。文章指出,从成本和临床角度来看,至少两到三个月的临终关怀可能是最佳的。(资料来源:美国国家电力公司2004年9月21日的新闻稿。)
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Hospice news
Research published in the September 2004 issue of the Journal of Pain and Symptom Management reports that patients enrolled in hospice care cost Medicare less. The study, “Medicare Cost in Matched Hospice and NonHospice Cohorts,” also revealed that hospice patients lived longer, on average, than similar patients who did not choose hospice care. Commissioned by the National Hospice and Palliative Care Organization (NHPCO) and conducted by the actuarial firm of Milliman, USA, the study’s goal was to identify cost differences between patients who elect and do not elect to receive Medicare-paid hospice benefits. According to the research, the majority of patients with 16 of the most common terminal diagnoses who choose hospice care cost Medicare less. Cost savings range from $1,115 for rectal cancer patients to $8,879 for congestive heart failure patients. Researchers also found that, on average, hospice patients lived longer. These life spans range from 20 days for patients with a diagnosis of gallbladder cancer to 69 days for those with breast cancer. “With almost 30 percent of Medicare costs going for all types of care delivered towards the end of life, an understanding of the cost benefits of hospice is important,” said J. Donald Schumacher, president and CEO of NHPCO. “However, discussions relating to costs should never cloud the most important issue— hospice provides the highest quality of compassionate care for patients and families.” A significant factor in this study is the unique methodology used to work towards eliminating selection bias. Selection bias has been a recognized problem in previous studies contrasting hospice versus nonhospice patients. Medicare health insurance claims and enrollment data were used to measure both costs and time until death, starting from narrowly defined dates. Indicative markers were identified that represented unambiguous points in the end stage of each disease. This study began tracking patients further upstream in a manner that researchers suggest addresses many selection bias concerns. The data source was Medicare health insurance claims and enrollment data from 5 percent Sample Beneficiary Standard Analytic Files for years 1998, 1999, and 2000. This 5 percent sample is created by the Centers for Medicare & Medicaid Services as a statistically representative, longitudinal data set. The research includes 8,700 patients who met the criteria for this study. The article points out that a period of at least two to three months of hospice care may be optimal from both a cost and clinical standpoint. (Source: NHPCO press release, September 21, 2004.)
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Association Between Oral Health Status and Survival Time in Terminally Ill Cancer Patients Hospice news 2005 Cumulative subject index Hospice news Call for manuscripts
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1